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ABSTRACT
Introduction: Obstetric hemorrhage is one of the major causes of maternal morbidity and mortality. 
Blood loss during cesarean section is almost twice than that in vaginal delivery. The aim of this study was 
to evaluate the efficacy of tranexamic acid to reduce blood loss in cesarean section and its side effects. 
Methods: A comparative study was done in 100 women undergoing cesarean section between December 
2015 to January 2017. The study group of 50 women received one gram intravenous tranexamic acid and 
the control group of 50 women did not receive tranexamic acid. Primary outcome measure was blood 
loss during cesarean section. Secondary outcome measures were drop in post-operative hemoglobin and 
hematocrit, change in pulse rate and blood pressure, need of additional uterotonics, auxiliary procedures 
to stop bleeding, blood transfusion rate and maternal and neonatal side effects of the drug. Results: Mean 
intraoperative blood loss in the study group was 443.62± 86.73ml; and in control group, 667.40±131.01ml 
(p<0.001). Mean postoperative drop in hemoglobin (g/dl) in the two groups were 0.82±0.27 and 1.86±0.64 
respectively (p<0.001). Mean postoperative drop in hematocrit in the two groups were 2.60±0.91 and 
5.49±1.97 respectively (p<0.001). Fourteen patients in the control group required additional uterotonics 
while none in the study group (p<0.001). There was no significant difference in the transfusion requirement 
(p=0.079). None of the mothers and the newborns had major side effects of drug. Conclusion: Tranexamic 
acid is a safe and effective drug to reduce blood loss in cesarean section.   
Keywords: Blood loss, Cesarean section, Tranexamic acid
Original Research Articlehttps://doi.org/10.22502/jlmc.7i2.292
Sarita Acharya,a,c Seoji Mishrab,c
Efficacy of Tranexamic Acid in Reducing Blood 
Loss in Cesarean Section: A Comparative Study.
How to cite this article:
Acharya S, Mishra S. Efficacy of Tranexamic Acid in Reducing 
Blood Loss in Cesarean Section: A Comparative Study. Journal 
of Lumbini Medical College. 2019;7(2):6 pages. DOI: https://
doi.org/10.22502/jlmc.v7i2.292 Epub: 2019 December 07.
INTRODUCTION:
Obstetric hemorrhage is one of the major causes 
of maternal morbidity and mortality in low-
income countries. It accounted for more than 27% 
of maternal deaths in low-income regions and 
approximately 16% in high-income regions.[1] Post-
partum hemorrhage (PPH) can kill a healthy woman 
within two hours of delivery.[2] Blood loss during 
cesarean section (CS) is almost twice than that in 
vaginal delivery and hence there is a need of a drug 
that reduces blood loss during CS. 
 Tranexamic acid  is a synthetic derivative of 
the amino acid lysine that exerts its anti-fibrinolytic 
effect through the reversible blockade of the lysine 
binding sites on plasminogen molecules.[3] It 
inhibits conversion of plasminogen to plasmin 
by tissue plasminogen activators.[4] It has been 
proved to reduce blood loss in elective surgery, 
trauma patients, dentistry  and menstrual blood loss. 
Tranexamic acid given within three hours of injury 
to a large cohort of adults with acute traumatic 
bleeding significantly reduced death due to bleeding, 
with no apparent increase in vascular occlusive 
events.[5] The optimal dosage and the route of 
administration in obstetric patients is unknown. For 
general fibrinolysis, a single dose of 1 gm or 10 mg/
kg by slow intravenous injection is recommended.
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[6]
The aim of this study was to evaluate the efficacy of 
tranexamic acid to reduce blood loss after cesarean 
section and its adverse effects.  
METHODS:
 This was a comparative study carried out from 
December 2015 to January 2017 in the Department 
of Obstetrics and Gynecology, Universal College of 
Medical Sciences. Ethical clearance was taken from 
the institutional review committee (UCMS/IRC/114 
/15). Written informed consents were obtained from 
the participants. 
Sample size was calculated by using the formula, 
N= 2x [Z (1-α/2) +Z β] 2 xσ2
  Δ2
where, significance level (α) was taken as 0.05, the 
desired power (β) as 0.80, standard deviation (σ) as 
1 and minimal clinically important difference (Δ) as 
0.55. The calculated sample size was 50.36, that is 51 
in each group. All patients with singleton pregnancy 
at term undergoing elective or emergency CS, except 
those who met exclusion criteria were included in the 
study. Exclusion criteria were concomitant uterine 
fibroid, active liver or kidney disease, bleeding 
disorders, patients on anticoagulants, antepartum 
hemorrhage, polyhydramnios, macrosomic baby, 
multiple pregnancy, allergy to tranexamic acid, 
pre-eclampsia, eclampsia, obstructed labour, 
previous two or more CS and cesarean under general 
anesthesia.
 Primary outcome measure was blood loss 
during CS, from incision to the closure of the skin. 
Secondary outcome measures were change in post-
operative hemoglobin and hematocrit at 24 hours, 
immediate and six hours post CS pulse rate and 
blood pressure, need of additional uterotonics, need 
for auxiliary procedures to stop bleeding (B-lynch 
suture, uterine artery ligation, internal iliac artery 
ligation and hysterectomy), and blood transfusion 
rate, and maternal and neonatal side effects of the 
drug used.
 Patients were assessed for selection criteria as 
soon as the decision for cesarean section was made. 
Investigations like hemoglobin, hematocrit, platelet, 
bleeding time (BT), clotting time (CT), prothrombin 
time/ international normalized ratio (PT/INR) were 
sent. Patients were randomized through random 
number tables into two groups: group one, the study 
group of 51 women receiving preemptive tranexamic 
acid and group two, the control group of 51 women 
without tranexamic acid. However, two patients one 
in each group were excluded from the final analysis 
because they underwent CS under general anesthesia 
due to failed spinal anesthesia. Injection tranexamic 
acid one gram was given intravenously to the patient 
in group one just before spinal anesthesia. Two 
separate suction jars were used to collect the amniotic 
fluid and the blood.  Blood loss after the placental 
delivery to closure of skin incision was noted from 
the suction jar. Difference of weight of tetra used 
before and after surgery was noted and blood loss 
was calculated. Pulse rate and blood pressure were 
recorded immediately and at six hours after CS. 
Hemoglobin and hematocrit were measured 24 hours 
after the surgery. 
 All data were collected in the preformed 
proforma and entered into MS Excel program. 
Statistical analysis was done using Statistical 
Package for the Social Sciences (SPSSTM ) software 
version 21. Student's t-test and Chi-square test 
were used for the comparison of quantitative and 
qualitative variables respectively between the two 
groups. p value <0.05 was considered statistically 
significant. 
RESULTS:
 Both groups were comparable in terms of 
age, gravidity, parity and period of gestation (Table 
1).
Table 1. Comparison of demographic variables 
between two study groups (N=100)
Variables Group 
1 (n=50)
(Mean ± 
SD)
Group 2 
(n = 50)
(Mean ± 
SD)
p
value*
Age (years) 25.71±4.6 25.20±4.6 0.82
Gravidity 1.56±0.73 1.6±0.78 0.79
Parity 0.50±0.64 0.48±0.58 0.87
Period of 
Gestation
39.33±1.40 39.46±1.15 0.61
* p value calculated by Student's t test.
 There were 11 cases of elective and 39 
cases of emergency cesarean in study group while 
13 elective and 37 cases of emergency cesarean in 
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control group (χ2 = 3.03, df =2 p=0.22). Fetal distress 
and previous cesarean were the most common 
indications in emergency and elective cesareans 
respectively. Pre-operative laboratory parameters 
including hemoglobin, hematocrit, platelet, PT/INR, 
APTT, BT, CT were comparable in both the groups 
(Table 2).
 Mean intraoperative blood loss during CS in 
the study group was 443.6 ml while in control group 
was 667.4ml which was significantly less (t=10.07, 
df=98, p<0.001). Similarly, postoperative drop in 
hemoglobin and hematocrit were significantly less in 
the study group receiving tranexamic acid compared 
to the control group (Table 3). 
 There were no significant differences in the 
heart rate and blood pressures measured immediately 
and at sixth postoperative hour between two groups 
(Table 4).
 Fourteen patients in control group required 
additional uterotonics while none in the study 
group received additional uterotonics, which was 
statistically significant (p<0.001). None of the 
patients in both groups required auxiliary surgical 
procedures to arrest hemorrhage.
Table 2.  Comparison of preoperative laboratory 
parameters between the study groups (N=100).
Variables Group 1 
(n=50)
Mean ± SD
Group 2 
(n=50)
Mean ± SD
p
value*
Hemoglobin
(g/dl)
11.32±1.03 11.58±1.07 0.21
Hematocrit 
(%)
34.07±3.09 33.79±6.64 0.78
Platelets
(X109/L)
2.02±0.41 2.56 ± 2.97 0.20
INR 1.4± 0.09 1.4±0.13 0.72
APTT 
(seconds)
34.4±1.22 34.15±1.14 0.32
BT 
(minutes)
1.48±0.34 1.55±0.37 0.28
CT 
(minutes)
4.14±0.47 4.11±0.77 0.85
* p value calculated by Student's t test.
 Three patients in control group required 
blood transfusion while none of them required in 
study group.
Table 3. Blood loss and post-operative blood parameters (N=100).
Variables Group 1
(Mean ± SD)
Group 2 
(Mean ± SD)
p value
Intraoperative blood loss(ml) 443.62± 86.73 667.40±131.01 <0.001
Post- operative hemoglobin at 24 hour (g/dl) 10.52±1.05 9.72±1.23 0.001
Postoperative drop in hemoglobin (g/dl) 0.82±0.27 1.86±0.64 <0.001
Post-operative hematocrit at 24 hour (%) 31.21±3.78 28.64±5.88 0.011
Postoperative drop in hematocrit (%) 2.60±0.91 5.49±1.97 <0.001
Table 4. Postoperative vital parameters (N=100).
Variables Group 1
(Mean ± SD)
Group 2 
(Mean ± SD)
p value
Immediate post-operative pulse rate 81.50±6.95 82.8±7.24 0.36
Six hours post-operative pulse rate 77.96±5.1 78.92±5.4 0.36
Immediate post-operative systolic blood pressure 119.48±7.94 118.28±6.84 0.42
Immediate post-operative diastolic blood pressure 72.28±7.2 72.48±6.78 0.88
Six hours post-operative systolic blood pressure 118.64±5.74 116.76±6.73 0.13
Six hours post-operative diastolic blood pressure 72.36±5.07 70.44±5.33 0.40
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 None of the patients had major side effects of 
tranexamic acid while nausea, vomiting and dizziness 
were present in 16%, 6% and 2% respectively.
  There was no significant difference in 
Apgar score of neonates in two groups at 5 and 10 
minutes with p value of 0.36 and 0.40 respectively. 
One neonate in the study group developed seizure 
which was managed with anticonvulsant.  
DISCUSSION:
 Postpartum hemorrhage is defined as blood 
loss of more than 500ml in vaginal delivery and 
1000ml in CS but can occur even with lesser amount 
than this in previously compromised patients like 
in anemia. Most of the maternal deaths occur soon 
after giving birth and almost all (99%) occur in 
low-income and middle-income countries.[7,8] 
One fourth of post partum maternal deaths is due 
to hemorrhage. Hemorrhage following CS is not 
uncommon and reducing the amount of CS blood 
loss carries special sense in countries like Nepal 
where many pregnant women are already anemic.
 Following placental delivery, the level 
of fibrinogen and fibrin decreases and tissue 
plasminogen activator activity also increases 
converting plasminogen to plasmin. This activation 
can take up to six to ten hours in the postpartum 
period.[9] Tranexamic acid which is a potent 
antifibrinolytic drug inhibits this conversion and 
helps in reducing blood loss following CS. The drug 
is cheaper, stable at room temperature, a fixed dose 
can be used without serious maternal and fetal side 
effects. 
 The patients in the study group had 
significantly less amount of intraoperative blood loss 
(443.62mL) compared to those in the control group 
(667.40mL) (p<0.001). This observation was similar 
to the result of other large studies on the subject 
matter.[10,11] As the amount of blood loss was 
significantly higher in the control group, the drop 
in postoperative hemoglobin and hematocrit were 
also higher compared to the study group, which was 
statistically significant (p<0.001). 
 Tranexamic acid can increase the pulse rate 
especially in elderly women. In this study there was 
no significant difference in the pulse rate among the 
two groups of patients taken immediately and at six 
hours following CS. This study did not show any 
significant change in post CS systolic and diastolic 
blood pressures among the two groups. Our results 
on the effect of tranexamic acid in postoperative 
vitals were consistent with other studies.[9,12] 
 Conventionally uterotonics are the only 
drugs used to reduce the postpartum blood loss in 
all modalities of deliveries and are effective as 
well. However, with the introduction of tranexamic 
acid which acts through different mechanism their 
use is declining. Fourteen patients in control group 
compared to none in the study group required 
additional uterotonics, which was statistically 
significant (p<0.001). Interestingly, none of the 
patients in either group required any auxiliary 
surgical procedures to arrest hemorrhage. Although 
tranexamic acid reduced the amount of blood loss 
significantly it did not have significant impact on 
the transfusion requirement in large studies like 
WOMAN trial.[13] In the current study, three patients 
in control group required blood transfusion while 
none of them required in study group (p=0.079).
 One of the most feared complications 
of tranexamic acid is the possibility of 
thromboembolism in the context of higher incidence 
of thrombosis during pregnancy and postpartum. 
The incidence of thrombosis during pregnancy and 
puerperium is five to six times higher than that in 
the general population and postpartum venous 
thromboembolism is more common than antepartum 
venous thromboembolism.[14] Unlike this none of 
our patients had thromboembolic events  Other large 
series also failed to demonstrate the increased risk of 
thromboembolism with the use of tranexamic acid 
during pregnancy.[13,15,16,17] Minor side effects 
like nausea, vomiting and dizziness were present 
in 16%, 8% and 2% of  patients respectively who 
received tranexamic acid. These minor symptoms 
did not increase the additional morbidity to the 
patients. In this study there was no maternal death 
in either group due to postpartum hemorrhage 
following CS. In a large series the use of tranexamic 
acid had significantly reduced maternal death due to 
postpartum hemorrhage without significant adverse 
effects.[13]   
 Tranexamic acid given to the mother did not 
show any adverse effects on neonatal outcome. There 
was no differences in Apgar score at 5 mins and at 
10 mins, seizure and thrombotic events in neonates 
of both the groups. These observations were similar 
to the results of another study.[10]  
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 There are certain limitations of this study. 
Firstly, the sample size is small in the context of 
increasing CS rate and the extent of the problem 
of post partum hemorrhage. Secondly, the standard 
method of estimation of blood loss was not applied 
due to technical problems.  
CONCLUSION: 
 The preemptive use of tranexamic acid 
before cesarean section effectively reduces blood 
loss and need for transfusion without significant 
adverse effects in the mother and the new born. 
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